Here are four things to know:
1. Organogenesis will become a wholly owned subsidiary of Avista.
2. Avista Capital Partners’ affiliates agreed to invest $92 million in the combined company in conjunction with the transaction.
3. The combined company’s anticipated initial enterprise value is approximately $673 million.
4. Organogenesis offers bioactive and acellular biomaterials products in advanced wound care, sports medicine and surgical biologics, including orthopedics and spine.
More articles on biologics:
6 things to know about Isto Biologics
Biologics may reduce work & activity impairment in axial spondyloarthritis patients, study shows: 4 things to know
Vericel appoints CMO: 3 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
